Silco Pharmaceuticals Past Earnings Performance
Past criteria checks 0/6
Silco Pharmaceuticals's earnings have been declining at an average annual rate of -21.5%, while the Pharmaceuticals industry saw earnings growing at 10.3% annually. Revenues have been declining at an average rate of 17.5% per year. Silco Pharmaceuticals's return on equity is 1.8%, and it has net margins of 10.1%.
Key information
-21.5%
Earnings growth rate
-26.5%
EPS growth rate
| Pharmaceuticals Industry Growth | 11.0% |
| Revenue growth rate | -17.5% |
| Return on equity | 1.8% |
| Net Margin | 10.1% |
| Last Earnings Update | 31 Mar 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses BreakdownBeta
How Silco Pharmaceuticals makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Mar 24 | 422 | 43 | 61 | 0 |
| 31 Dec 23 | 436 | 48 | 65 | 0 |
| 30 Sep 23 | 437 | 50 | 66 | 0 |
| 30 Jun 23 | 465 | 69 | 70 | 0 |
| 31 Mar 23 | 418 | 68 | 70 | 0 |
| 31 Dec 22 | 474 | 82 | 74 | 0 |
| 30 Sep 22 | 504 | 79 | 75 | 0 |
| 30 Jun 22 | 559 | 84 | 81 | 0 |
| 31 Mar 22 | 552 | 88 | 73 | 0 |
| 31 Dec 21 | 561 | 87 | 76 | 0 |
| 30 Sep 21 | 546 | 86 | 75 | 0 |
| 30 Jun 21 | 601 | 85 | 80 | 0 |
| 31 Mar 21 | 681 | 84 | 100 | 0 |
| 31 Dec 20 | 691 | 76 | 103 | 0 |
| 30 Sep 20 | 740 | 88 | 113 | 0 |
| 30 Jun 20 | 734 | 83 | 110 | 0 |
| 31 Mar 20 | 814 | 163 | 129 | 0 |
| 31 Dec 19 | 856 | 167 | 133 | 0 |
| 30 Sep 19 | 930 | 168 | 141 | 0 |
| 30 Jun 19 | 919 | 162 | 138 | 0 |
| 31 Mar 19 | 920 | 106 | 132 | 0 |
| 31 Dec 18 | 924 | 105 | 134 | 0 |
| 30 Sep 18 | 910 | 104 | 133 | 0 |
| 30 Jun 18 | 918 | 105 | 132 | 0 |
| 30 Jun 17 | 907 | 103 | 130 | 0 |
| 30 Jun 16 | 886 | 119 | 130 | 0 |
| 31 Dec 15 | 851 | 117 | 126 | 0 |
| 31 Dec 14 | 810 | 60 | 120 | 0 |
| 31 Dec 13 | 998 | 141 | 124 | 0 |
Quality Earnings: SILCOPHL has a large one-off gain of BDT18.6M impacting its last 12 months of financial results to 31st March, 2024.
Growing Profit Margin: SILCOPHL's current net profit margins (10.1%) are lower than last year (16.4%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: SILCOPHL's earnings have declined by 21.5% per year over the past 5 years.
Accelerating Growth: SILCOPHL's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: SILCOPHL had negative earnings growth (-37.5%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (-2.6%).
Return on Equity
High ROE: SILCOPHL's Return on Equity (1.8%) is considered low.